Skip to Main Content
An official website of the United States government

Browse Lab Results > 2009-0564

Trial Summary

About CDAS Project, PI, Publications: DNA Methylation Markers and Prostate Cancer Risk

Datasets

Site: Prostate

Inclusion Criteria:

  • No Personal History of any Cancer
  • No Reported Cancers During Trial
  • White, Non-Hispanic
  • With 10+ ug of DNA Available
  • With 100+ ug of DNA and 4+ Vials of Buffy Coat
  • In Pegasus
  • With All Necessary Vial-Level Requirements

Matching Factors:

  • None

Match Ratio: N/A

Match Technique: N/A

Analytes:

  • DNA Methylation

Number of Controls: 80


Site: Prostate

Inclusion Criteria:

  • White, Non-Hispanic
  • No Prior History of Any Cancer
  • No Rare Cancers
  • No Reported Cancer During Trial in Controls
  • With Buffy Coat
  • With T0 and T5 Buffy Coat
  • With Pegasus GWAS Data Available

Matching Factors:

  • None

Match Ratio: N/A

Match Technique: N/A

Analytes:

  • DNA Methylation

Number of Cases: 40

Number of Controls: 40


Site: Prostate

Inclusion Criteria:

  • Males
  • White, Non-Hispanic
  • Not From Hawaii Center
  • Prior History of Any Cancer
  • No Controls with Prostate Cancer Prior to Censor Date
  • Rare Cancers in Controls
  • Specimen Available (1+ ug DNA)
  • Cases: Pre-Diagnostic Specimen Available (1+ ug DNA)
  • Cases: Prostate Cancer is First Reported Cancer
  • Cases: Previously selected for CGEMS, BPC3 or Prostate Aim1

Matching Factors:

  • Age at Randomization (5 year intervals)
  • Fiscal Year of Randomization
  • Year of Blood Draw

Match Ratio: 1 to 1

Match Technique: Frequency matching only non-cases as controls.

Additional Matching Comments: Cases and controls were matched on year of exit using the NDI 07 prostate cancer method

Analytes:

  • ALU
  • LINE-1

Number of Cases: 707

Number of Controls: 707